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Introduction {#sec1}
============

The nucleosome remodeling and deacetylation (NuRD) complex is an abundant, highly conserved multiprotein chromatin remodeler initially defined as a transcriptional repressor ([@bib47], [@bib48], [@bib51], [@bib52]). NuRD activity facilitates cell fate transitions in a range of different organisms and developmental contexts ([@bib44]). The complex combines two enzymatic activities in the form of class I lysine deacetylation, encoded by the Hdac1 and 2 proteins, with the Swi/Snf-type ATPase and nucleosome remodeling of Chd4. Additionally, the complex contains histone chaperone proteins Rbbp4 and Rbbp7, one of the zinc-finger proteins Gatad2a or Gatad2b, two MTA proteins (Mta1, Mta2, and/or Mta3), Cdk2ap1, and Mbd2 or Mbd3 ([@bib3], [@bib18], [@bib28]). With the exceptions of the histone deacetylase proteins and Rbbp4 and 7, these proteins have been found only within the NuRD complex.

NuRD is an abundant chromatin-associated protein complex, and its components have been reported to physically interact with a wide repertoire of transcription factors. Indeed, a few of these have been shown to recruit NuRD to specific DNA sequences to influence transcription of individual target genes (e.g., [@bib2], [@bib15], [@bib22]). Genome-wide mapping of chromatin binding patterns of NuRD components has shown them to occupy virtually all active enhancers and promoters in a variety of cell types ([Figure S1](#mmc1){ref-type="supplementary-material"}; [@bib5], [@bib10], [@bib26], [@bib43], [@bib46]). Rather than being recruited to every active enhancer and promoter by individual sequence-specific transcription factors, these global localization data are more consistent with a model in which NuRD has a general affinity for open chromatin or possibly for the transcription machinery. Sequence-specific transcription factors might then act to locally increase NuRD concentrations at individual target loci.

The Mbd3 protein was originally identified by sequence similarity to the methyl-CpG binding protein Mecp2, but the putative methyl-CpG binding domain of Mbd3 contains mutations that prevent binding to methylated DNA ([@bib11], [@bib40]). Mbd3 is required for lineage commitment of pluripotent cells and is essential for early mammalian development ([@bib44]). Notably, the methyl-CpG binding domain-like region of Mbd3 is dispensable in normal differentiation and development. Recent structural work has found that Mbd3 physically links two biochemical and functional NuRD subcomplexes: a remodeling subcomplex containing Chd4, Gatad2a/b, and Cdk2ap1 and a histone deacetylase subcomplex containing the HDAC, MTA, and RBBP proteins ([Figure S1](#mmc1){ref-type="supplementary-material"}A; [@bib25], [@bib54]). Mbd3 acts as a molecular bridge between these subcomplexes and thus maintains the structural integrity of NuRD.

Mbd2 and Mbd3 are mutually exclusive components of NuRD, and Mbd2/NuRD and Mbd3/NuRD have been found to exhibit distinct but overlapping functions ([@bib10], [@bib12], [@bib21]). In mouse embryonic stem cells (ESCs), Mbd3/NuRD activity modulates the transcription of pluripotency-associated genes, maintaining expression within a range that allows cells to effectively respond to differentiation signals ([@bib37]). Despite profound developmental defects, Mbd3 deficiency in ESCs results in only moderate gene expression changes, with the majority of genes changing by less than two-fold ([@bib26], [@bib38]). Rather than turning genes on or off, Mbd3/NuRD activity serves to fine-tune gene expression in ESCs. Although this amounts to many small transcriptional changes, the cumulative effect of this is nevertheless an acute phenotype: the inability of pluripotent cells to undergo lineage commitment.

How the two distinct enzymatic activities of NuRD individually influence the transcriptional machinery is not clear. NuRD activity results in loss of H3K27 acetylation, providing a substrate for PRC2-mediated trimethylation at some sites ([@bib38]). The nucleosome remodeling activity of Chd4 generally increases nucleosome density at target sites and facilitates lineage commitment through control of gene expression probability ([@bib5], [@bib22], [@bib29], [@bib30], [@bib32]), but exactly how Chd4-depdendent nucleosome remodeling mechanistically impacts transcription is unknown. A much more detailed understanding of the relative functions of these two activities is required to understand how transcription is so precisely controlled in developmental contexts.

In this study, we set out to determine how NuRD fine-tunes gene expression. Using an inducible ESC system with fine temporal resolution, we show that transcriptional control by the NuRD complex is primarily exerted through its chromatin remodeling activity. NuRD acts at regulatory sequences to increase nucleosome density, which in turn influences the ability of transcription factors, coactivators, and RNA polymerase II to associate with those sequences. We further demonstrate that NuRD-dependent nucleosome rearrangements are used by cells to control protein access to enhancers during lineage commitment. This shows how the dual enzymatic activities of one chromatin-modifying complex impact the transcription machinery to precisely control transcription levels during cell state transitions.

Results {#sec2}
=======

NuRD Fine-Tunes Active Transcription in Mouse ESCs {#sec2.1}
--------------------------------------------------

Two NuRD component proteins, the ATP-dependent helicase Chd4 and the scaffold protein Mbd3, associate with chromatin extensively in ESCs ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Mbd3 occupancy is almost completely coincident with Chd4, consistent with the presence of Mbd3 exclusively within the NuRD complex ([Figure S1](#mmc1){ref-type="supplementary-material"}B). In contrast, less than half of all Chd4 sites are also bound by Mbd3, in line with data showing that Chd4 also functions independently of NuRD ([@bib31], [@bib32]). Binding of both Chd4 and Mbd3 correlates strongly with indicators of active promoters and enhancers, such as H3K27Ac, H3K4Me1, H3K4Me3, P300, and the initiating form of RNA polymerase II (PolII-S5P; [Figure S1](#mmc1){ref-type="supplementary-material"}C), as well as with pluripotency-associated transcription factors Oct4, Nanog, Esrrb, and Klf4. In contrast, NuRD component binding is anti-correlated with a mark of silent chromatin (H3K9Me3) and with another histone modification deposited across transcribed gene bodies (H3K36Me3). Weak correlation is seen with Ezh2 and trimethylated H3K27, consistent with NuRD cooperating with PRC2 at a subset of loci in ESCs ([@bib38]). NuRD and Chd4 co-occupy nearly all active enhancers and active promoters in ESCs ([Figure S1](#mmc1){ref-type="supplementary-material"}D), indicating that NuRD is tightly associated with the active transcriptional machinery. Despite the widespread presence of NuRD on sites of active transcription, loss of the Mbd3 component (and dissolution of Mbd3/NuRD) results in only moderate changes in gene expression ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Taken together, these data demonstrate that Mbd3/NuRD associates with sites of active transcription and functions not to turn genes on or off but rather to fine-tune gene expression in ESCs.

An Inducible Mbd3 System Allows Induction of NuRD Activity at High Temporal Resolution {#sec2.2}
--------------------------------------------------------------------------------------

We wished to understand how the enzymatic activities of the NuRD complex regulate gene expression. We therefore sought to measure the consequences of acute NuRD recruitment on chromatin structure and transcription of NuRD-responsive genes. We employed a system that allowed us to restore NuRD activity to a cell in which the functional complex is lacking and subsequently monitored the impact on chromatin and transcription over time. The "b" isoform of the Mbd3 protein ([@bib11]) fused to mouse estrogen receptor (ER) domains at both the N and C termini was expressed in *Mbd3*-null ESCs ([Figure 1](#fig1){ref-type="fig"}A). The "b" isoform of Mbd3 lacks the N-terminal half of the methyl-CpG binding domain-like region and is the predominant isoform in mouse ESCs ([Figures 1](#fig1){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}A). In the absence of tamoxifen, the ER-Mbd3b-ER protein is confined to the cytoplasm, and cells adopt an *Mbd3*-null phenotype, in that they are resistant to differentiation ([Figures 1](#fig1){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}B; [@bib38]). In the absence of nuclear Mbd3, the NuRD component proteins Mta3 and Gatad2b show reduced protein stability ([Figure 1](#fig1){ref-type="fig"}B). Although Chd4 remains associated with existing Gatad2b protein in the nucleus, there is little detectable interaction between Chd4 and components of the NuRD histone deacetylase subcomplex, such as Mta1 or Hdac1 ([Figure 1](#fig1){ref-type="fig"}C). Upon introduction of tamoxifen to the culture media, ER-Mbd3b-ER rapidly translocates into the nucleus, restoring the stability of NuRD complex components ([Figures 1](#fig1){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}C) and the biochemical interactions between Chd4 and components of the deacetylase subcomplex ([Figure 1](#fig1){ref-type="fig"}C). Differentiation competence is also re-established ([Figure S2](#mmc1){ref-type="supplementary-material"}B), indicating the restoration of NuRD function. Thus, our system allows the selective induction of NuRD formation and function in a highly controllable manner.Figure 1Mbd3 Induction Restores NuRD Activity to *Mbd3*-Null ESCs(A) Model of the induction system: *Mbd3*-null ESCs (left) contain ER-Mbd3b-ER (green diamonds, ER-M3b-ER) in the cytoplasm. Upon addition of tamoxifen, ER-M3b-ER enters the nucleus.(B) Nuclear extracts from Mbd3-inducible ESCs at different times after tamoxifen addition or from wild-type ESCs (WT) were probed with antibodies indicated at right. In the α-Mbd3 panel, the location of the ER-Mbd3b-ER transgene is indicated with an arrow, as are the locations of endogenous Mbd3 isoforms in WT cells. Sin3A and Pcna act as loading controls. Protein sizes are shown at left in kilodaltons.(C) Chd4 was immunoprecipitated from nuclear protein extracts across tamoxifen induction time course and probed with antibodies indicated at right. IgG, immunoglobulin G (IgG) control; Input, 10% input; IP, Chd4 immunoprecipitation. Protein sizes are shown at left in kilodaltons.(D) ChIP-qPCR for Chd4 (blue lines), Mbd3 (black lines), and IgG (gray lines) across the promoter and an enhancer of NuRD target gene *Ppp2r2c* at 0 and 24 hr of tamoxifen treatment. x axes show locations relative to the annotated transcription start site of *Ppp2r2c*. N ≥ 3 biological replicates. See also [Figure S2](#mmc1){ref-type="supplementary-material"}C.(E) ChIP-qPCR at the peak of Mbd3 ChIP signal in (D) plotted across a time course of tamoxifen addition. Significant enrichment of Mbd3 relative to no tamoxifen occurs from 15 min onward (^∗∗∗∗^p \< 0.0001, ^∗∗^p \< 0.01, and ^∗^p \< 0.05 using a two-tailed t test). N ≥ 3 biological replicates.(F) Input-normalized ChIP signal across WT Mbd3 peaks plotted for ER-ChIP in uninduced cells (left) or after 48 hr of tamoxifen treatment (middle) and for Mbd3-ChIP in WT ESCs (right). Mean signal is plotted across the top.(G) qRT-PCR using nascent RNA of indicated genes over 48 hr of the time course of tamoxifen addition (mean of relative expression ± SEM; plotted relative to time 0). Tamoxifen was added to either the *Mbd3* inducible line (in red) or to the parental, *Mbd3*-null line as a control (in black). N ≥ 3 biological replicates.(H) Unsupervised clustering of nascent RNA-seq during the Mbd3 induction time course. Significant changes (\|FC\| \> 2; p \< 0.05) in transcript level compared to time 0 are shown by gray bars in the left-hand panels. Triplicate samples were prepared and sequenced for each time point. See also [Figures S1](#mmc1){ref-type="supplementary-material"}, [S2](#mmc1){ref-type="supplementary-material"}, and [S3](#mmc1){ref-type="supplementary-material"}.

The induced Mbd3 protein was detectable by chromatin immunoprecipitation (ChIP) on known NuRD target sequences between 15 and 30 min after tamoxifen addition, where enrichment continued to increase over 48 hr ([Figures 1](#fig1){ref-type="fig"}D, 1E, and [S2](#mmc1){ref-type="supplementary-material"}C). Binding at both 24 hr and 48 hr is highly correlated with Mbd3 ChIP sequencing (ChIP-seq) signal measured in wild-type cells, demonstrating that ER-Mbd3b-ER is properly targeted to chromatin in our induction system ([Figures 1](#fig1){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}D). NuRD component protein Gatad2b showed increased enrichment at NuRD target sites within 1 hr of tamoxifen addition, consistent with the assembly and recruitment of the NuRD complex to chromatin as a consequence of Mbd3 induction ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Levels of Chd4 enrichment at some, but not all, Mbd3 target loci increased over this time course ([Figures 1](#fig1){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}C). However, the presence of Mbd3 had no detectable impact on the distribution of Chd4-bound sites ([Figure S2](#mmc1){ref-type="supplementary-material"}D), indicating that Chd4 is able to bind chromatin independently of Mbd3 and the rest of the NuRD complex, though Mbd3 may serve to stabilize Chd4-chromatin interaction.

Restoration of NuRD activity had a rapid impact on gene expression. Coincident with NuRD complex formation and association to chromatin ([Figures 1](#fig1){ref-type="fig"}C and 1E), changes in the levels of nascent transcripts were detectable within 30 min of Mbd3 induction and increased steadily through 48 hr ([Figures 1](#fig1){ref-type="fig"}G and 1H). Distinct classes of transcriptional changes were evident: both increases and decreases in expression ≤4 hr after Mbd3 induction or after a lag of 1 or 2 days. As was seen in steady-state conditions, the impact of NuRD induction on transcriptional output was modest, with the majority of genes changing by less than 2-fold even by 48 hr ([Figures 1](#fig1){ref-type="fig"}G, 1H, and [S3](#mmc1){ref-type="supplementary-material"}A--S3C). This observation is consistent with a transcriptional modulatory function for the complex, rather than with it simply turning genes on or off. Persistent and significant changes in steady-state mRNA levels were first detectable by total RNA-seq 4--8 hr post-tamoxifen addition and also increased steadily through 48 hr ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). Gene expression changes seen upon Mbd3 induction were consistent with those observed in *Mbd3*^*−/−*^ ESCs ([Figure S3](#mmc1){ref-type="supplementary-material"}D). The timescale for induction of NuRD complex formation, recruitment to chromatin, and subsequent changes in transcriptional activity thus provides a means to probe the molecular changes that underlie NuRD-dependent gene regulation.

Histone H3 Lysine 27 Acetylation Changes Follow but Do Not Precede NuRD-Dependent Transcriptional Changes {#sec2.3}
---------------------------------------------------------------------------------------------------------

The NuRD complex comprises two enzymatic activities: class I protein deacetylation in the Hdac1 and 2 proteins and nucleosome remodeling through Chd4. We reasoned that NuRD would affect its transcriptional modulation through one or both of these two activities. Considering the former, we previously showed that acetylation of histone H3 lysine 27 (H3K27Ac), a mark generally associated with active transcription, is anticorrelated with NuRD activity ([@bib38]). We therefore investigated whether induction of NuRD would have an immediate impact on levels of H3K27 acetylation at genes showing a transcriptional response to NuRD induction.

Genes for which a change in mRNA levels was detectable within 8 hr of tamoxifen addition showed no significant differences in H3K27Ac within this time frame (repressed or activated early; [Figures 2](#fig2){ref-type="fig"}A and 2B, left panels). A change in H3K27Ac levels at these genes was detectable 48 hr after tamoxifen addition, commensurate with the direction of transcriptional change ([Figures 2](#fig2){ref-type="fig"}A and 2B, middle panels). Genes at which a change in mRNA levels was detectable only 24--48 hr after tamoxifen addition showed no significant change in H3K27Ac levels even after 48 hr (repressed or activated late; [Figures 2](#fig2){ref-type="fig"}A and 2B, right panels). We followed alterations in H3K27 acetylation at finer temporal resolution by ChIP-qPCR at two NuRD-repressed genes (*Ppp2r2c* and *Htra1*; [Figure 1](#fig1){ref-type="fig"}G). H3K27Ac levels at both promoters decreased only after transcription had already been affected, showing slight initial increases within four hours post-tamoxifen exposure followed by a gradual decrease through 48 hr ([Figure 2](#fig2){ref-type="fig"}C). Genome-wide, levels of H3K27Ac showed a slight decrease at NuRD-bound loci after four hours, but initial levels were restored by 24 hr ([Figure 2](#fig2){ref-type="fig"}D). Changes in H3K27 acetylation are therefore unlikely to drive the acute transcriptional changes observed after NuRD induction but rather may act to reinforce them.Figure 2H3K27Ac Levels Do Not Immediately Correlate with NuRD-Induced Gene Expression Changes(A) H3K27Ac ChIP-seq data normalized to H3 ChIP-seq at indicated time points of tamoxifen addition are plotted across a metagene for genes showing significant reduction in mRNA levels within 8 hr ("repressed early") or only after 24--48 hr ("repressed late"). Data are plotted as mean ± 95% confidence intervals (N = 3 biological replicates).(B) As in (A) but for genes showing significant increases early (≤8 hr) or late (24--48 hr).(C) ChIP-qPCR for H3K27Ac plotted relative to H3 ChIP across the *Ppp2r2c* and *Htra1* transcription start sites for 0, 24, and 48 hr following tamoxifen addition. Mean ± SEM; N ≥ 3 biological replicates. (Below) Data at the peak of enrichment from the panels above are displayed across the time course of tamoxifen exposure. Mean ± SEM (^∗∗^p \< 0.01 and ^∗^p \< 0.05 relative to 0 hr). N = 2--5 biological replicates.(D) ChIP-seq for H3K27Ac normalized to H3 ChIP for each time point of Mbd3 induction centered at peaks of NuRD binding ± 2 Kb, classified into active and inactive enhancers, promoters, or other sequences. Mean signal for each category is plotted across the top.

NuRD Induction Rapidly Induces Changes in Chromatin Structure {#sec2.4}
-------------------------------------------------------------

The other enzymatic activity contained within NuRD is the ATPase-dependent nucleosome remodeling capacity of Chd4. To determine whether this activity is used by the complex to drive transcriptional changes, we assessed how induction of NuRD impacted chromatin structure using micrococcal nuclease (MNase) digestion followed by high-throughput sequencing (MNase-seq). MNase cuts DNA efficiently at relatively open chromatin but digests less efficiently at sites associated with DNA binding proteins or nucleosomes and can therefore be used to map regions of open chromatin and to define sequences frequently associated with nucleosomes. Mbd3 induction resulted in a rapid (\<30 min) and pronounced increase in protection from MNase digestion at Chd4- and Mbd3-bound sites genome-wide ([Figure 3](#fig3){ref-type="fig"}A). This manifested as an increase in MNase protection at sites of relatively open chromatin, such as enhancers and transcription start sites ([Figure 3](#fig3){ref-type="fig"}B). NuRD activity had no detectable influence over the spacing of positioned nucleosomes adjacent to CTCF-bound sites ([Figure 3](#fig3){ref-type="fig"}A), in contrast to reported effects for cells lacking the NuRF or SNF2H chromatin remodelers ([@bib4], [@bib19], [@bib34], [@bib49]). Considering that Chd4 targeting does not change significantly over this time course ([Figure S2](#mmc1){ref-type="supplementary-material"}D), this pronounced Mbd3-induced change in chromatin structure may indicate that Mbd3 affects not only the stability of Chd4 association with chromatin but also its activity.Figure 3NuRD Controls Nucleosome Density at Regulatory Sequences(A and B) MNase-seq data collected after 0 or 30 min or 24 hr of tamoxifen treatment are plotted (A) across peaks of enrichment for indicated proteins defined in WT cells or (B) across indicated features (n = number of peaks/feature). Data are plotted as mean ± 95% confidence intervals. p values were calculated for each time point relative to time 0 for the center of the feature indicated with a dashed line. ^∗∗∗^p \< 0.001. N = 3 biological replicates.(C and D) MNase-qPCR data (mean ± SEM) for the 0- and 24-hr time points plotted across an enhancer and the TSS for *Ppp2r2c* (C) and for *Bmp4* (D). The x axis indicates Kb relative to the annotated TSS for each gene. Overlaid in red are ChIP-qPCR data for Mbd3-ER at 24 hr post-tamoxifen addition. The blue arrows indicate the positions further analyzed in panels at right, where the horizontal line shows the mean. A schematic of each gene is shown above the ChIP-qPCR panels. Filled and open boxes represent coding and non-coding exons, respectively, and the red box below the line indicates the position of the relevant enhancer. N ≥ 6 biological replicates. ^∗∗∗∗^p \< 0.0001, ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01, and ^∗^p \< 0.05 relative to 0 hr using a two-tailed t test.

MNase-qPCR enabled us to determine more precisely how Mbd3/NuRD influenced chromatin structure at two specific genes responsive to NuRD activity: *Ppp2r2c* and *Bmp4* ([Figure 1](#fig1){ref-type="fig"}G). Positioned nucleosomes could be detected as regularly spaced peaks of MNase-resistant chromatin in *Mbd3*-null ESCs at enhancers and promoters associated with these genes ([Figures 3](#fig3){ref-type="fig"}C and 3D). Induction of Mbd3 activity imparted very little change in this structure at the *Ppp2r2c* promoter but resulted in pronounced changes at an enhancer located within intron 1 of the gene ([Figure 3](#fig3){ref-type="fig"}C). Specifically, DNA at position +8.6 kb in null cells rapidly lost MNase protection, which we interpret as a loss of a positioned nucleosome, and positions adjacent to those, at +8.3 kb (which coincides with the peak of Mbd3 binding) and +8.7 kb, gained protection with similar kinetics, consistent with increased nucleosome occupancy. Similarly, at the *Bmp4* promoter, a MNase-resistant site coinciding with the peak of Mbd3 binding (+0.12 Kb) was quickly lost, and MNase resistance was gained at flanking sites (−0.14 Kb and +0.31 Kb; [Figure 3](#fig3){ref-type="fig"}D). These precise changes in MNase sensitivity occurred rapidly (between 30 min and 1 hr) in response to NuRD induction and indicate active remodeling of nucleosome positioning within these regulatory elements. Mbd3-dependent changes to chromatin structure at these regulatory sequences were detectable prior to a detectable change in transcription of either gene ([Figure 1](#fig1){ref-type="fig"}G), consistent with induction, rather than response to a change in gene expression.

MNase sensitivity is usually interpreted in relation to nucleosome occupancy and positioning, but it is formally possible that some instances of nuclease protection could arise from NuRD occupancy, masking or exposing specific nucleosome-bound sites. If changes in MNase sensitivity are observed due to NuRD-mediated nucleosome movement, these should be dependent upon ATPase-dependent chromatin remodeling by Chd4 ([@bib47], [@bib48], [@bib51], [@bib52]). ESCs constitutively expressing an ATPase mutant Chd4 ([@bib8]) were not viable in long-term culture, so to test this, we expressed a doxycycline-inducible cDNA encoding either wild-type or an ATPase mutant Chd4 in Mbd3 inducible ESCs ([Figure 4](#fig4){ref-type="fig"}A). We reasoned that the overexpressed mutant protein would compete with endogenous Chd4 for binding at sites of action, where the ATPase mutant version would be unable to remodel nucleosomes and would thus impede any remodeling-dependent functions of NuRD. Chd4 expression was induced 18 hr prior to onset of the tamoxifen time course, which gave robust expression of both wild-type and mutant Chd4 ([Figures 4](#fig4){ref-type="fig"}A and 4B). We could detect both wild-type and ATPase mutant Chd4 associating with chromatin to similar extents, which did not interfere with the association of induced Mbd3 ([Figure S4](#mmc1){ref-type="supplementary-material"}). When tamoxifen was added in the presence of the ATPase mutant Chd4, nucleosome movement at both the *Ppp2r2c* enhancer and *Bmp4* promoter was considerably slower than when tamoxifen was added either in the presence of wild-type Chd4 or in cells in which mutant Chd4 expression was not induced ([Figure 4](#fig4){ref-type="fig"}C). This also resulted in delayed transcriptional repression of both genes ([Figure 4](#fig4){ref-type="fig"}D). We therefore conclude that the observed changes in MNase protection and subsequent changes in transcription are dependent upon ATPase and nucleosome remodeling activity of Chd4 and are thus likely to result from NuRD-dependent chromatin remodeling.Figure 4Nucleosome Remodeling Is Chd4 Dependent(A) Timeline of the experiment. DOX was added to induce expression of the WT or mutant Chd4 cDNA 18 hr prior to tamoxifen addition, which induced nuclear translocation of Mbd3-ER.(B) Nuclear extracts from ESCs expressing either the WT or ATPase mutant (Mut) Chd4 transgene (Chd4 TG) with and without DOX treatment were probed with an anti-Chd4 (left) or an anti-FLAG antibody (right). "No TG," ESCs with no Chd4-transgene. Lamin B1 serves as a loading control. Protein sizes are given at left in kilodaltons.(C) MNase qPCR as in [Figures 3](#fig3){ref-type="fig"}C and 3D for indicated locations in the *Ppp2r2c* enhancer and *Bmp4* promoter in ESCs expressing the WT Chd4 transgene (left), the ATPase mutant Chd4 transgene (middle), and in cells in which expression of the ATPase mutant Chd4 was not induced with DOX (right). ^∗∗∗∗^p \< 0.0001, ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01, and ^∗^p \< 0.05 relative to 0 hr using a two-tailed t test. N = 4 or 5 biological replicates.(D) Expression data of nascent RNA measured by qRT-PCR for *Ppp2r2c* or *Bmp4* across the tamoxifen induction time course in ESCs expressing the WT (Chd4 WT) or ATPase mutant (Chd4 ATPase mutant) CHD4 are plotted over time. N = 6--9 biological replicates. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

NuRD Activity Alters the Protein Binding Repertoire of Regulatory Sequences {#sec2.5}
---------------------------------------------------------------------------

What effect might a change in chromatin structure have at sites of active transcription? Mbd3 and Chd4 binding patterns are highly correlated with those of pluripotency-associated transcription factors ([Figure S1](#mmc1){ref-type="supplementary-material"}C; [@bib26], [@bib46]), so we hypothesized that NuRD may act generally to regulate transcription factor access to regulatory sequences. To test this hypothesis, we performed ChIP-seq for two important pluripotency-associated sequence-specific transcription factors (TFs), Klf4 and Nanog, and for a component of the kinase module of the Mediator complex, Med12, across the Mbd3 induction time course. No changes in the levels of nuclear Nanog, Klf4, or Med12 protein were observed across the time series ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Mbd3 induction resulted in an initial loss of Nanog enrichment at target sites globally, followed by an increase in enrichment through 24 hr ([Figure 5](#fig5){ref-type="fig"}A). Similarly, Klf4 enrichment was initially reduced at its targets upon Mbd3 induction, but levels were restored by 4 hr ([Figure 5](#fig5){ref-type="fig"}A). Global Med12 enrichment remained stable during the first 4 hr of Mbd3 induction but increased significantly by 24 hr ([Figure 5](#fig5){ref-type="fig"}A). Thus, despite genome-wide reduction of chromatin accessibility at NuRD target sites ([Figure 3](#fig3){ref-type="fig"}A), this does not result in a global decrease in TF binding and indeed appears to enhance Nanog and Med12 binding to target sites in the longer term.Figure 5NuRD Controls Transcription Factor Access to Chromatin(A) Protein binding at indicated time points across ChIP-seq peaks defined in WT cells (Nanog and Klf4) or at the most significant peaks identified at the 24-hr time point in the in the Mbd3 inducible cell line (Med12). Data are plotted as mean ± 95% confidence intervals. The later time points were compared with 0 hr, and significant differences in mean are indicated as ^∗∗^p \< 0.01 or ^∗∗∗^p \< 0.001 using a two-tailed t test.(B) Protein binding or MNase protection are plotted across sites defined as having significantly increased binding in *Mbd3*-null ESCs versus WT cells (Nanog and Klf4) or were called as peaks at 0 hr, but not at 24 hr, in the Mbd3 induction time course (Med12; higher in KO) or the opposite (higher in WT) for each protein. The later time points were compared with 0 hr, and significant differences in mean are indicated as ^∗^p \< 0.05 or ^∗∗∗^p \< 0.001 using a two-tailed t test.(C) ChIP-qPCR for indicated proteins at the peak of binding for each feature ([Figure S5](#mmc1){ref-type="supplementary-material"}B) at the indicated *Ppp2r2c* or *Bmp4* enhancers across the time course of tamoxifen exposure. A schematic of each gene is shown above the ChIP-qPCR panels. Time after tamoxifen addition in hours is indicated along the x axis. Mean ± SEM is plotted for all points. ^∗∗^p \< 0.01 and ^∗^p \< 0.05 relative to 0 hr using a two-tailed t test. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

The above data indicate that NuRD does not regulate TF binding globally, but it remains possible that the complex can control TF binding at specific NuRD- and TF-binding loci. If NuRD-mediated chromatin remodeling directly regulates TF binding at a subset of target sites, we would expect to see a decrease in chromatin accessibility at sites that lose TF binding and vice versa. To this end, we first identified sites at which Nanog or Klf4 binding was significantly higher in wild-type cells ("higher in -WT") or in *Mbd3*-null cells ("higher in KO"). For Med12, we performed a similar analysis using *Mbd3*-null cells and inducible cells after 24 hr of induction. These are sites that we predict would gain or lose TF/Med12 binding, respectively, during Mbd3 induction. We then compared protein occupancy and MNase accessibility at these two different classes of sites for each protein across the time course. Sites with highest Nanog, Klf4, or Med12 binding in *Mbd3*-null cells all showed a significant loss of protein enrichment within 30 min of Mbd3 induction ([Figure 5](#fig5){ref-type="fig"}B, left panels). For all three proteins, this corresponded to an average increase in MNase protection across binding sites: for Nanog sites, this increase had begun by 30 min and continued to increase thereafter, although at Klf4 and Med12 sites, the greatest shift in MNase protection occurred within 30 min. These data are consistent with a model in which NuRD-mediated increases in nucleosome density interferes with or evicts Nanog, Klf4, and/or Med12 from this subset of bound sites.

Sites at which Nanog, Klf4, or Med12 binding was lower in Mbd3 KO cells than in WT cells (i.e., sites predicted to gain binding in response to NuRD activity) showed no consistent pattern of behavior. At Nanog sites, Mbd3 induction was associated with a rapid loss of MNase protection, consistent with NuRD acting to make these sites more accessible, although increases in Nanog protein binding were not detected until 4--24 hr ([Figure 5](#fig5){ref-type="fig"}B, right panels). At Klf4 and Med12 sites, induction of Mbd3 was accompanied by a rapid (30 min) increase in MNase protection. At Klf4 sites, this was first associated with a loss of Klf4 binding, consistent with the initial exclusion of Klf4 from these sites; however, subsequent restoration and gain of Klf4 enrichment occurred with no further change in chromatin accessibility ([Figure 5](#fig5){ref-type="fig"}B). At Med12 sites, the rapid increase in MNase protection did not appear to impact Med12 binding, and the predominant gain of Med12 enrichment between 4 and 24 hr was not associated with a large change in chromatin accessibility. Together, these data support a model in which NuRD-dependent chromatin remodeling can displace chromatin-bound proteins. Increased protein binding, however, is not tightly correlated to MNase protection and thus may be an indirect effect of NuRD activity.

To verify this model, we examined TF binding behavior in detail by ChIP-qPCR for Klf4, Nanog, Esrrb, Oct4, Med12, and P300 at two enhancers that both show changes in nucleosome structure during the NuRD induction time course ([Figures 3](#fig3){ref-type="fig"}C and 3D). The intronic *Ppp2r2c* enhancer showed an acute and sustained loss of all chromatin-associated proteins tested upon Mbd3 induction, coincident with rapid stabilization of the +8.3 Kb nucleosome ([Figures 3](#fig3){ref-type="fig"}C and [5](#fig5){ref-type="fig"}C), resulting in an overall reduction in TF and coactivator binding at this site ([Figure S5](#mmc1){ref-type="supplementary-material"}B). In contrast, at the upstream *Bmp4* enhancer, an initial loss of protein binding, consistent with a gain of MNase protection at the −23 Kb position, was followed by gradual recovery of protein binding levels over time ([Figures 3](#fig3){ref-type="fig"}C and [5](#fig5){ref-type="fig"}D), resulting in either no change or a slight increase in protein biding by 24 hr ([Figure S5](#mmc1){ref-type="supplementary-material"}C). We conclude that an acute NuRD-dependent increase in local nucleosome density can result in eviction of chromatin-bound proteins. Rather than creating inaccessible or "closed" chromatin, however, this initial clearance of proteins from regulatory sequences allows for a new protein-binding repertoire to be established. This resetting of regulatory element occupancy upon a now NuRD-defined nucleosome topology may result in altered recruitment and association of individual DNA-binding proteins.

NuRD Induction Displaces RNA Polymerase II from Transcription Start Sites {#sec2.6}
-------------------------------------------------------------------------

NuRD has a rapid and pronounced impact upon MNase sensitivity across transcription start sites globally ([Figure 6](#fig6){ref-type="fig"}A). Most notably, there is a large increase in MNase protection associated with the positioned nucleosomes immediately up- and downstream of transcriptional start sites (TSSs) at 30 min of Mbd3 induction. Although this increase is less pronounced by 24 hr, overall, there is a persistent rise in protection across TSSs globally relative to the uninduced state. This effect is seen irrespective of whether the associated genes show increased, decreased, or unchanged expression levels 48 hr after Mbd3 induction ([Figure 6](#fig6){ref-type="fig"}A).Figure 6NuRD Induction Results in Loss of RNA Polymerase II from Transcription Start Sites and a Transient Reduction in Nascent RNAs(A) MNase-seq reads plotted as in [Figure 3](#fig3){ref-type="fig"}A across all TSS or just those showing reduced (down genes) or increased (up genes) expression after 48 hr of tamoxifen treatment. p values were calculated as in [Figure 3](#fig3){ref-type="fig"}A. ^∗∗∗^p \< 0.001.(B) ChIP-seq signal for RNA polymerase II (S5P) plotted as in (A).(C) Schematic of traveling ratio calculation. The blue line represents S5P ChIP-seq signal across a paused gene (TR = 0.75), whereas the red line shows signal across an unpaused gene (TR = 0.5). TSS, transcription start site; TTS, "transcription termination site" (defined as polyA addition site).(D) Cumulative traveling ratio calculated from RNA polymerase II (S5P) ChIP-seq data at time 0 (dark purple), 30 min (0.5H; light purple), 4 hr (green), and 24 hr (blue). CDF, cumulative density function. p values are given for each time point compared to time 0.(E) Nascent RNA-seq plotted as in (A). Only data for the + strand are plotted as confidence intervals. N = 3 biological replicates. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Paused RNA polymerase II, which is found widely across transcription start sites in metazoan cells, is often associated with nucleosome depletion ([@bib9]). To address how NuRD-induced changes in nucleosome occupancy at TSSs correspond to the status of the transcription machinery, we performed ChIP-seq for the initiating form of RNA polymerase II (phosphorylated at the serine 5 position of the C-terminal repeat; S5P). Mbd3 induction resulted in a rapid (≤30 min) decrease in the amount of S5P RNA polymerase II associated with transcription start sites globally ([Figure 6](#fig6){ref-type="fig"}B). This decrease continued through 4 hr, and then levels had increased again by 24 hr. This pattern was seen regardless of whether the associated genes showed altered transcription after Mbd3 induction ([Figure 6](#fig6){ref-type="fig"}B). Throughout the time course, no changes in global levels of S5 phosphorylated RNA polymerase II were detectable by immunoblotting ([Figure S5](#mmc1){ref-type="supplementary-material"}A).

Mbd3-dependent increase in nucleosome density is most pronounced immediately downstream of the transcription start site. If this was the cause of RNA polymerase II displacement, we would expect to see a more pronounced loss of RNA polymerase II at the 5′ ends of genes than in gene bodies. To test this, we measured traveling ratios across the Mbd3 induction time course for all TSSs ([Figure 6](#fig6){ref-type="fig"}C). Traveling ratios give an indication of the relative abundance of RNA polymerase at promoters versus the gene body ([@bib1]). They can be used to indicate the degree of transcriptional pausing, although initiation rate and elongation rate also influence traveling ratio ([@bib6]). Induction of NuRD activity resulted in a global decrease in traveling ratio within 30 min of Mbd3 induction, which reached a minimum at 4 hr ([Figure 6](#fig6){ref-type="fig"}D). This was true regardless of the direction of expression change ([Figure S6](#mmc1){ref-type="supplementary-material"}). Together, these data indicate that a NuRD-directed increase in nucleosome occupancy at transcription start sites globally results in a decrease in TSS-associated RNA polymerase II occupancy.

It was curious that both the increase in nucleosome occupancy and the decrease in associated RNA polymerase II occurred irrespective of whether associated genes were repressed, activated, or unchanged during the Mbd3 induction time course. To investigate this in more detail, we monitored the change in nascent RNA-seq reads across transcription start sites. This showed a specific effect at transcripts associated with the very 5′ ends of genes, precisely where the largest changes in nucleosome and RNA polymerase II occupancy are observed. Specifically, induction of Mbd3 resulted in a sharp decrease in transcripts localizing within the first 750 bp of genes after 30 min, which then increased to a steady-state level by 24 hr ([Figure 6](#fig6){ref-type="fig"}E). Examining those genes specifically repressed after Mbd3 induction (down genes) revealed a similar decrease in transcripts at 30 min, and these remained reduced through 48 hr, consistent with a reduction of transcription at these genes by 48 hr. Genes activated by Mbd3 induction (up genes) again showed a significant decrease in nascent RNA mapping to 5′ ends of the genes at 30 min, but levels increased again by 24 and 48 hr.

Thus the initial response to acute Mbd3 induction is the same for all genes: increase in nucleosome density, loss of RNA polymerase II, and reduction in transcriptional output associated with 5′ ends. At a subset of genes, re-establishment of RNA polymerase II levels results in a stable reduction in overall transcription (down genes), although at other genes, the result of re-establishment is an overall increase in stable transcript levels (up genes). Therefore, by resetting the local nucleosome landscape and clearing the TSS of RNA polymerase II so that a new transcriptional state is established, one chromatin remodeling complex can act to repress some genes and activate others. The activity exerted by NuRD is the same at all target sites, namely altering nucleosome density. Yet the impact this has differs at specific genes, presumably due to variation in the architecture of the regulatory element in question.

NuRD Controls Nucleosome Structure and Enhancer Access during an ESC State Transition {#sec2.7}
-------------------------------------------------------------------------------------

NuRD facilitates exit from the self-renewing state in ESCs by modulating gene expression levels ([@bib37]). We asked whether the NuRD-dependent control of chromatin structure and protein binding identified in our inducible system also occurred at NuRD target genes during exit from the ESC state. ESCs cultured in self-renewal conditions express naive pluripotency markers, such as *Klf4* and *Zpf42* (*Rex1*), but not the primed pluripotency marker *Otx2*. Upon withdrawal of self-renewal factors, cells exit naive pluripotency, downregulating *Klf4* and *Zfp42* and upregulating *Otx2.* These initial effects are observed in both WT and *Mbd3*-null cells, but in the absence of Mbd3, gene expression changes proceed more slowly ([Figure 7](#fig7){ref-type="fig"}A). These kinetic differences enabled us to explore the mechanisms underlying transcriptional regulation in the presence or absence of endogenous Mbd3 as cells underwent a cell state transition. In contrast to our inducible system that illustrates the mechanistic effects of acute NuRD recruitment to sites of action, this allows us to monitor in detail the molecular events occurring at a set of regulatory regions involved in developmentally relevant transcriptional changes. We focused on changes at three enhancers after 24 hr in differentiation conditions, as this is the point immediately preceding a difference in the kinetics of silencing of *Klf4* and *Zfp42* and activation of *Otx2* between WT and *Mbd3*-null ESCs ([Figure 7](#fig7){ref-type="fig"}A).Figure 7Inappropriate Enhancer Chromatin Remodeling and Protein Binding in *Mbd3*-Null ESCs during Lineage Commitment(A) Expression of *Klf4*, *Zfp42*, and *Otx2* over a differentiation time course relative to that in WT cells in 2iL conditions. Mean ± SEM; N ≥ 3 biological replicates.(B) ChIP-qPCR for Mbd3-FLAG in WT (black) and *Mbd3*-null (magenta) ESCs across indicated enhancer sequences in 2iL (self-renewing conditions \[SR\]) or after 24 hr in differentiation conditions (24h Diff). Mean ± SEM; N ≥ 4 biological replicates.(C) MNase-qPCR profiles across enhancers associated with *Klf4*, *Zfp42*, and *Otx2* are plotted for WT (black) or *Mbd3*-null ESCs (blue) in SR and after 24h Diff. Mean ± SEM; N ≥ 3 biological replicates.(D) ChIP-qPCR for Med12 and Med1 in WT (black) or *Mbd3*-null ESCs (magenta) before and after 24 hr in differentiation media. Data are plotted relative to levels in WT at time 0. Mean ± SEM; N ≥ 3 biological replicates.(E) ChIP-qPCR for either total (NTD) or serine 5 phosphorylated (S5P) RNA polymerase II as in (D). Data are plotted relative to time 0. Mean ± SEM; N ≥ 3 biological replicates.(F) Model of how NuRD controls transcription. In the absence of Mbd3 (top left), NuRD does not form and regulatory sequences for a hypothetical gene adopt a specific nucleosome structure (gray spheres), are bound by transcription factors (TFs), and associate loosely with Mediator and with RNA polymerase II at the start of a gene (gray arrow). Adding back Mbd3 results in rapid NuRD reformation, an increase in nucleosome density, and eviction of TFs, Mediator, and RNA polymerase I from the regulatory sequences in the first 30 min (top middle). By 24 hr, the NuRD-dictated nucleosome structure has adopted a new transcription factor repertoire and is more stably associated with Mediator. This is the WT situation (top right). When cells are induced to differentiate, NuRD holds the nucleosome structure in place while Mediator is excluded in preparation for a change in transcriptional output (bottom right). In the absence of Mbd3 (bottom left), the differentiation signal results in a shift in nucleosome structure that does not exclude Mediator, making it less likely that the required change in transcription will occur.

Enhancers associated with *Klf4*, *Zfp42*, and *Otx2* were bound by Mbd3 in self-renewing conditions, though Mbd3 enrichment increased after 24 hr in differentiation conditions ([Figure 7](#fig7){ref-type="fig"}B). Induction of differentiation in WT cells resulted in little overall change in the nucleosome structure at any of the enhancers analyzed after 24 hr ([Figure 7](#fig7){ref-type="fig"}C). In self-renewing *Mbd3*^−/−^ cells, there were small but distinct differences to the nucleosome patterns of the *Zfp42* and *Otx2* enhancers relative to those seen in WT cells ([Figure 7](#fig7){ref-type="fig"}C). Induction of differentiation in *Mbd3*-null ESCs resulted in substantial changes to the MNase protection pattern of all enhancers analyzed, indicating that NuRD normally acts to stabilize the nucleosome structure of these enhancers during a change in transcription ([Figure 7](#fig7){ref-type="fig"}C).

During differentiation-induced transcriptional changes in WT cells, components of the Mediator complex, Med12 and Med1, showed reduced enrichment at *Klf4* and *Zfp42* enhancers but remained stable at the *Otx2* enhancer ([Figure 7](#fig7){ref-type="fig"}D). In the absence of NuRD, Med12 levels were reduced at the enhancers in self-renewing conditions consistent with our ChIP-seq data ([Figure 6](#fig6){ref-type="fig"}A). *Mbd3*-null cells maintained in 2iL conditions are under strict selection to maintain appropriate expression levels of genes in the pluripotency regulatory network, and the reduced association of Mediator components with these enhancers may be part of how cells adapt to not having NuRD activity. Unlike in WT cells, though, no further reduction in Mediator component enrichment was seen upon induction of differentiation in the absence of Mbd3, and at the *Zfp42* and *Otx2* enhancers, Med12 enrichment actually increased relative to the undifferentiated state ([Figure 7](#fig7){ref-type="fig"}D).

Consistent with the observed changes in transcriptional output of each gene in WT cells, induction of differentiation also resulted in reduced association between the *Klf4* or *Zfp42* enhancers with RNA polymerase II and with increased association at the *Otx2* enhancer ([Figure 7](#fig7){ref-type="fig"}E). This change in enhancer-RNA polymerase II interaction in *Mbd3*^*−/−*^ cells was altered at enhancers corresponding to all three genes. At the *Klf4* and *Zfp42* enhancers, the interaction was abnormally high upon differentiation, consistent with a defect in silencing, and at *Otx2*, the degree of interaction did not increase as much as in WT cells, consistent with impaired gene activation.

Together, these data show that NuRD activity is required to maintain an appropriate nucleosome structure and protein binding repertoire at three different regulatory sequences when the associated genes are undergoing a change in expression status: in this case, as a result of a developmental transition. Assuming that this holds true more generally across the genome, we propose a model in which appropriate transcriptional response to a given stimulus requires NuRD-dependent control of local nucleosome structure and that dictates the ability of different proteins to stably associate with that sequence ([Figure 7](#fig7){ref-type="fig"}F). By controlling the nucleosome structure of regulatory sequences, NuRD acts at enhancers and promoters to regulate transcriptional programs. We suggest that it is this fine-tuning of enhancer responsiveness and transcriptional output on a genome-wide scale that is required for a pluripotent cell to properly orchestrate a lineage commitment event.

Discussion {#sec3}
==========

Although many chromatin remodeling proteins are essential for mammalian development, the actual mechanics of how they influence transcription remain ill defined. In particular, the NuRD complex has been something of a puzzle: although this complex was originally defined as a co-repressor, it is present at all sites of active transcription in ESCs and serves to both activate and repress transcription of a similar number of genes. Here, we use an inducible system with fine temporal resolution to resolve this apparent paradox. Induction of NuRD activity results in rapid reorganization of nucleosome structure at enhancers and promoters genome-wide, clearing some chromatin-bound proteins and RNA polymerase II from these sites. This initial eviction of chromatin-bound proteins is followed by re-establishment of the protein binding repertoire, which may then differ from the original configuration (model, [Figure 7](#fig7){ref-type="fig"}F). At most genes, this resetting of enhancers and promoters has only a transient impact on nascent RNA production at transcription start sites. At a subset of genes, however, this revised protein binding landscape results in altered mRNA output, with similar numbers of genes showing increased or decreased expression. We further show that NuRD-mediated control of nucleosome structure at enhancers of three developmentally relevant target genes occurs during transcriptional responses during a developmental transition.

NuRD's broad distribution across all sites of active transcription in ESCs is consistent with recruitment arising from an affinity for open chromatin or the presence of some component of the RNA polymerase machinery. Whereas it is clear that, in some cases, transcription factors can recruit NuRD to chromatin, Mbd3 enrichment is quickly lost at transcribed genes upon addition of transcription inhibitors (data not shown), supporting targeting mechanisms more tightly linked to the transcription process itself. The downstream effect of nucleosome remodeling activity differs in a locus-specific manner. What governs whether a gene is up- or downregulated in response to NuRD remains to be defined but is likely to be determined by the underlying DNA sequence and affinity of transcription factors for sites therein.

All of the actively transcribed genes in ESCs could be deemed "direct NuRD targets" simply by virtue of having Mbd3/Chd4 ChIP peaks at their promoters ([Figure S1](#mmc1){ref-type="supplementary-material"}). Using standard practice, each of the ∼2,000 genes that show differential expression between *Mbd3* WT and *Mbd3* KO ESCs could therefore be argued to be "directly regulated by NuRD". This does not distinguish between gene expression changes occurring as a primary consequence of Mbd3 loss and those that occurred as a consequence of the cells having been selected to survive and proliferate in the absence of Mbd3/NuRD. Differentiating between these two scenarios is important for understanding how NuRD, or indeed any chromatin remodeler, regulates transcription. Furthermore, combining ChIP-seq data with observations from steady state knockout lines led us to propose that NuRD can act as both activator and repressor of transcription ([@bib39]); however, indirect effects could also be responsible for this observation. Using our inducible system, we are able to determine direct consequences of NuRD activity, clearly defining a chain of events starting with reformation of NuRD and ending with stable changes in transcription. This not only confirms that NuRD is capable of both increasing and decreasing transcription but also provides a model for how one remodeling complex can influence transcription in opposing directions at distinct loci.

The *in vivo* targets of the lysine deacetylase activity of NuRD have not been defined, although anti-correlation of H3K27Ac levels with NuRD function has been observed in steady-state conditions ([@bib38]). *In vitro*, the histone deacetylase components of the NuRD complex show little substrate specificity ([@bib54]). In our system, changes in levels of H3K27Ac are not associated with early stages of transcriptional regulation but rather follow gene expression changes ([Figure 2](#fig2){ref-type="fig"}). This result is consistent with studies in yeast and flies, which found that transcription induction in some contexts does not require covalent histone modifications ([@bib13], [@bib33], [@bib53]). A recent study found that histone deacetylase activity was dispensable for NuRD-dependent silencing of Ikaros target genes in pre-B cells but rather served to reinforce silencing ([@bib22]). The synergistic interaction between NuRD and PRC2 is most consistent with this maintenance role for NuRD-associated deacetylase activity.

In a cellular context, chromatin remodelers do not act in isolation. The pattern of NuRD binding to chromatin closely resembles that of the activating chromatin remodeling complex BAF ([@bib14], [@bib17]). Although NuRD acts to increase nucleosome density ([Figure 3](#fig3){ref-type="fig"}), BAF has the opposite effect, acting to remove nucleosomes from regulatory sequences ([@bib5], [@bib27], [@bib29]). Why should these two opposing chromatin remodeling activities be present at the same regulatory sequences in ESCs? If the two complexes are indeed acting in direct opposition at the same sites but their activities are closely matched, then their opposing activities could serve to finely tune the activity levels of regulatory sequences. A balance of nucleosome remodeling activity at enhancers could similarly provide fine tuning of enhancer activity but also serve to make them particularly responsive to inductive (or repressive) signals. For example, an enhancer where BAF activity dominates may have low nucleosome density and be easily accessible to binding by an inductive TF. If the activity of NuRD dominated at that same enhancer, then the nucleosome density would be higher, resulting in a less accessible enhancer, which might require a higher concentration of TF for induction. This is consistent with our findings that absence of NuRD does not prevent signal-induced changes in gene expression but rather changes the kinetics and/or magnitude of the transcriptional changes ([Figure 7](#fig7){ref-type="fig"}; [@bib37]). Such fine-tuning of promoter or enhancer chromatin may well have no overall impact on many genes, for which a level of NuRD- or BAF-modulated enhancer tweaking has no influence on transcriptional output. This is consistent with the observations that loss of either NuRD or BAF activity has no impact on the transcript levels of the vast majority of genes in ESCs ([Figure S1](#mmc1){ref-type="supplementary-material"}E; [@bib14], [@bib46]). In a developmental context, such as during ESC differentiation, where cells switch from one transcriptional program to another, this balance between remodeling activities at regulatory elements is critical.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Chd4, mouse monoclonalAbcamRRID:[AB_2229454](nif-antibody:AB_2229454){#intref0010}ER, rabbit polyclonalSanta Cruz BiotechnologyRRID:[AB_631471](nif-antibody:AB_631471){#intref0015}Esrrb, mouse monoclonalR&D SYSTEMSRRID:[AB_2100412](nif-antibody:AB_2100412){#intref0020}GATAD2A, rabbit monoclonalAbcamRRID:[AB_1952305](nif-antibody:AB_1952305){#intref0025}GATAD2B, rabbit polyclonalBethyl LabsRRID:[AB_937934](nif-antibody:AB_937934){#intref0030}H3, rabbit polyclonalAbcamRRID:[AB_302613](nif-antibody:AB_302613){#intref0035}H3 K27ac, rabbit polyclonalAbcamRRID:[AB_2118291](nif-antibody:AB_2118291){#intref0040}H3 K4me3, rabbit polyclonalMilliporeRRID:[AB_1163444](nif-antibody:AB_1163444){#intref0045}Hdac1, rabbit polyclonalAbcamRRID:[AB_305705](nif-antibody:AB_305705){#intref0050}Hdac2, rabbit polyclonalSanta CruzRRID:[AB_2118563](nif-antibody:AB_2118563){#intref0055}Klf4, goat polyclonalR&D SystemsRRID:[AB_2130245](nif-antibody:AB_2130245){#intref0060}LaminB1, rabbit polyclonalAbcamRRID:[AB_2616597](nif-antibody:AB_2616597){#intref0065}Mbd3, rabbit monoclonalAbcamab157464Mbd3, rabbit polyclonalBethyl LabsRRID:[AB_1998980](nif-antibody:AB_1998980){#intref0070} BATCH NUMBER 1Med1, rabbit polyclonalBethyl LabsRRID:[AB_577241](nif-antibody:AB_577241){#intref0075}Med12, rabbit polyclonalBethyl LabsRRID:[AB_669756](nif-antibody:AB_669756){#intref0080}Mta1, rabbit monoclonalCell SignalingRRID:[AB_10705601](nif-antibody:AB_10705601){#intref0085}Mta1/2, goat polyclonalSanta CruzRRID:[AB_649541](nif-antibody:AB_649541){#intref0090}Mta2, mouse monoclonalAbcamRRID:[AB_2146939](nif-antibody:AB_2146939){#intref0095}Mta3, rabbit polyclonalProteintechRRID:[AB_2298003](nif-antibody:AB_2298003){#intref0100}Nanog, rabbit polyclonalBethyl LabsRRID:[AB_386108](nif-antibody:AB_386108){#intref0105}P300, rabbitSanta CruzRRID:[AB_2616339](nif-antibody:AB_2616339){#intref0110}PCNA, mouse monoclonalSanta CruzRRID:[AB_628110](nif-antibody:AB_628110){#intref0115}Pou5f1, goat polyclonalSanta CruzRRID:[AB_653551](nif-antibody:AB_653551){#intref0120}Rbbp4, rabbit monoclonalAbcamRRID:[AB_1603754](nif-antibody:AB_1603754){#intref0125}RNA Polymerase II CTD4H8 (SER 5P), mouse monoclonalMilliporeRRID:[AB_309852](nif-antibody:AB_309852){#intref0130}RNA Polymerase II N-20 (Polr2a), rabbitSanta Cruzsc-899 XRNA Polymerase II NTD D8L4Y (Polr2a), rabbit monoclonalCell SignalingRRID:[AB_2687876](nif-antibody:AB_2687876){#intref0135}Sin3a, rabbit polyclonalSanta CruzRRID:[AB_2187760](nif-antibody:AB_2187760){#intref0140}**Chemicals, Peptides, and Recombinant Proteins**TrizolLife Technologies15596018Micrococcal nucleaseNew England BiolabsM0247S4-thiouridineSigmaT45094-hydroxytamoxifenSigmaH7904Mouse ES cell line: Mbd3-3xFLAG knock-in/homozygous floxedBH LabBHAMouse ES cell line: Mbd3^Δ/Δ^BH LabBHAKO**Deposited Data**Mbd3 Inducible ES cells, time 0, 0.5, 4, 24h: 48h InputThis paperE-MTAB-6804Mbd3 Inducible ES cells, time 0, 0.5, 4, 24h: Nanog ChIPThis paperE-MTAB-6804Mbd3 Inducible ES cells, time 0, 0.5, 4, 24h: Klf4 ChIPThis paperE-MTAB-6804Mbd3 Inducible ES cells, time 0, 0.5, 4, 24h: Med12 ChIPThis paperE-MTAB-6804Mbd3 Inducible ES cells, time 0, 0.5, 4, 24h: RNA Polymerase II S5P ChIPThis paperE-MTAB-6804Mbd3 Inducible ES cells, time 0, 24h, 48h: Chd4 ChIPThis paperE-MTAB-6804Mbd3 Inducible ES cells, time 0, 24h, 48h: FLAG ChIPThis paperE-MTAB-6804Mbd3 Inducible ES cells, time 0, 1h, 4h, 8h, 24h, 48h: H3K27Ac ChIPThis paperE-MTAB-6804Mbd3 Inducible ES cells, time 0, 1h, 4h, 8h, 24h: H3K4Me3 ChIPThis paperE-MTAB-6804Mbd3 Inducible ES cells, time 0, 1h, 4h, 8h, 24h, 48h: H3 ChIPThis paperE-MTAB-6804Mbd3^FLAG/-^ InputThis paperE-MTAB-6804Mbd3^FLAG/-^ Chd4 ChIPThis paperE-MTAB-6804Mbd3^FLAG/-^ FLAG ChIPThis paperE-MTAB-6804Mbd3^FLAG/-^ Klf4 ChIPThis paperE-MTAB-6804Mbd3^FLAG/-^ Nanog ChIPThis paperE-MTAB-6804Mbd3^−/−^ InputThis paperE-MTAB-6804Mbd3^−/−^ Chd4 ChIPThis paperE-MTAB-6804Mbd3^−/−^ Klf4 ChIPThis paperE-MTAB-6804Mbd3^−/−^ Nanog ChIPThis paperE-MTAB-6804Mbd3 Inducible ES cells, time 0, 0.5, 1, 4, 24, 48h nascent RNA seqThis paperE-MTAB-6805Mbd3 Inducible ES cells, time 0, 0.5, 1, 4, 24, 48h mRNA seqThis paperE-MTAB-6806Mbd3 Inducible ES cells, time 0, 0.5, 24h MNase-seqThis paperE-MTAB-6807**Other**WT ES RNA-seq datasetPMID: [27471257](pmid:27471257){#intref0145}E-MTAB-4566Mbd3^−/−^ ES RNA-seq datasetPMID: [27471257](pmid:27471257){#intref0150}E-MTAB-4566H3K27Me3 ChIP-seq datasetPMID: [22541430](pmid:22541430){#intref0155}GSE23943H3K36Me3 ChIP-seq datasetPMID: [22541430](pmid:22541430){#intref0160}GSE23943H3K9Me3 ChIP-seq datasetPMID: [22541430](pmid:22541430){#intref0165}GSE23943H3K27Ac ChIP-seq datasetPMID: [24905168](pmid:24905168){#intref0170}GSE56138H3K4Me1 ChIP-seq datasetPMID: [24905168](pmid:24905168){#intref0175}GSE56138H3K4Me3 ChIP-seq datasetPMID: [24905168](pmid:24905168){#intref0180}GSE56138Ezh2 ChIP-seq datasetPMID: [22541430](pmid:22541430){#intref0185}GSE23943Esrrb ChIP-seq datasetPMID: [27471257](pmid:27471257){#intref0190}E-MTAB-4565Nanog ChIP-seq datasetPMID: [27471257](pmid:27471257){#intref0195}E-MTAB-4565Oct4 ChIP-seq datasetPMID: [27471257](pmid:27471257){#intref0200}E-MTAB-4565Klf4 ChIP-seq datasetPMID: [27471257](pmid:27471257){#intref0205}E-MTAB-4565EP300 ChIP-seq datasetPMID: [24905168](pmid:24905168){#intref0210}GSE56138

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Brian Hendrich (<Brian.Hendrich@cscr.cam.ac.uk>, \@BDH_Lab).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Tissue culture {#sec4.3.1}

Mouse embryonic stem (ES) cells were cultured in 2i/LIF (2iL) media on gelatin-coated plates unless otherwise specified. *Mbd3* conditional and null ES cell lines have been described ([@bib16], [@bib46]) and were created in an E14Tg2a (XY) background. Translocation of Mbd3b protein to the nucleus was induced with 4-hydroxytamoxifen added directly to the culture media to a final concentration of 0.4 nM for varying times as indicated. Alkaline phosphatase assays were performed by plating 1000 cells into a 6-well plate and expanding for 4 days prior to staining according to the manufacturer's protocol (Sigma). N = 3 to 12 wells per condition. Colonies were scored blind to genotype.

Method Details {#sec4.4}
--------------

### Immunoprecipitation and western blotting {#sec4.4.1}

Immunoprecipitation and western blotting were carried out using standard methods. Antibodies and concentrations used are listed in [Table S1](#mmc2){ref-type="supplementary-material"}. All original, uncropped blots are available at Mendeley Data: <https://doi.org/10.17632/2whjxyxyc9.1>

### ChIP, ChIP-seq and ChIP-seq data analyses {#sec4.4.2}

Chromatin immunoprecipitation (ChIP) was performed using standard protocols. Fixation was carried out using 1% formaldehyde 10 minutes at room temperature and quenched with 150 mM glycine. DNA was fragmented in the presence of 0.4% SDS using a Bioruptor sonication instrument (Diagenode) producing a size range of 200 to 300 bp. Antibodies used are listed in [Table S1](#mmc2){ref-type="supplementary-material"}. Locus-specific primers used for quantitative PCR are listed in [Table S2](#mmc3){ref-type="supplementary-material"}. ChIP-seq libraries were prepared using the NEXTflex Rapid DNA-seq kit (Illumina) and sequenced at the CRUK Cambridge Institute Genomics Core facility (Cambridge, UK) on the Illumina platform.

ChIP-seq libraries were filtered for adaptor sequences and aligned to the mouse reference genome (mm10/GRCm38) using Bowtie (v1.0.1/1.1.1) ([@bib20]) with parameters -y --best--strata--nomaqround and filtered for uniquely mapped reads (-m 1). Duplicate reads were removed with Picard tools (v1.114/1.76). Enriched regions (or peaks) for Mbd3, Chd4 and transcription factors were called with MACS2 (v2.1.0.20140616/20150420) ([@bib23]) with default parameters using DNA input as control and retaining all statistically enriched regions (FDR \< 1%). ChIP-seq peaks were annotated relative to Ensembl genomic features with PeakAnalyzer ([@bib41]). NuRD peaks were defined as the union of Mbd3 and Chd4 peaks which overlap by at least 1bp.

Klf4 and Nanog regions that were differentially bound in wild-type and *Mbd3*^*−/−*^ cells were identified using diffBind ([@bib45]). First, a set of consensus peaks found in at least two replicates was defined. Read counts were then calculated across those peaks and input counts subtracted, followed by differential analysis reporting the significantly bound regions (FDR \< 0.05).

Regions enriched for histone modifications were detected relative to corresponding sequenced input-DNA or H3 controls using MACS2 with broad peak mode at FDR threshold of 5%. Where biological replicates were available, consensus peaks were identified in the pooled dataset (obtained by pooling reads from all replicates). Peaks were filtered for regions blacklisted by ENCODE.

Values for read densities were adjusted by subtracting those found in the corresponding input experiment normalized for sequencing depth with deeptools (v1.6.0). We calculate ChIP-seq enrichment in 10bp bins as Reads per Genomic Content (RPGC).

Regions enriched for H3K4me1 were categorized into inactive enhancers (without H3K4me3 enrichment) or active enhancers (with overlapping H3K27ac and p300 enrichment). If more than one published dataset was available for a given histone modification or p300, only peaks called in all datasets were considered in enhancer identification.

Traveling ratio was calculated for all genes in Ensembl 75, defined as the ratio of RNA Polymerase II Serine 5 phosphorylation density (RPKM) in promoters to that in the gene body and promoter ([Figure 6](#fig6){ref-type="fig"}C). The promoter-proximal region is defined using a fixed window of −2Kb to 500bp around the gene start. The gene body is from +501bp to the gene end. Only genes with at least 1 RPKM reads in the gene promoter and body were included in these analyses.

### RNA-seq and expression analysis {#sec4.4.3}

Metabolic labeling of cells for purification of nascent transcript was carried out as described ([@bib35]). Cells were treated with tamoxifen for the times indicated and pulse labeled with 500 μM 4-thiouridine for 15 minutes prior to harvesting in Trizol (Life Technologies) for RNA purification. For isolation of total RNA for sequencing, cells were harvested in Trizol and processed according to manufacturer's instructions.

Libraries for sequencing were prepared using the NEXTflex Rapid Directional RNA-seq kit (Illumina) or SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian (Takara Bio) and sequenced as above. Individual expression assays were carried out using gene-specific TaqMan probes (Life Technologies).

RNA-seq libraries were mapped against the mouse reference genome mm10 using GSNAP (gmap-2014- 12-17) ([@bib50]) with parameters "--m 7 --i 1 --N 1 --w 100000 --E 100 --n 10." Gene read counts were calculated with HTSeq (v0.6.1) based on gene annotation from Ensembl release 75, and normalization and differential expression analysis were performed using the R package DESeq2 ([@bib24]) with the default model. We identified differentially expressed genes at FDR-adjusted *p*-values less than 0.05. For time series analyses differential expression was assessed for all pairwise comparisons against the 0 h time point.

### MNase-seq and MNase qPCR {#sec4.4.4}

For nucleosome positioning analyses, cells were grown in 2iL conditions (supplemented with tamoxifen as noted). Cells were harvested, washed in ice cold PBS and resuspended in ice cold lysis buffer (10mM Tris-HCl pH7.4, 10mM NaCl, 3mM MgCl~2~, 0.5% IGEPAL, 150mM spermine and 500mM spermidine) at a concentration of 10^6^ cells/ml. 1ml aliquots were centrifuged at 300 × *g* for 10 min at 4°C and pellets washed in 1ml digestion buffer (10mM Tris-HCl pH7.4, 15mM NaCl, 60mM KCl, 150mM spermine and 500mM spermidine). MNase digestion was carried out in 100ul digestion buffer containing 1mM CaCl and 2000U/ml micrococcal nuclease (New England Biolabs) at 24°C for 15min with shaking. The reaction was terminated using an equal volume of stop buffer (digestion buffer containing 20mM EDTA, 2mM EGTA) before RNase and Proteinase K treatment. Monosomal DNA was isolated by phenol chloroform extraction followed by gel purification and either used for library preparation in the case of MNase-seq or for quantitative PCR. Locus-specific primers and their positions relative to annotated transcription start sites are listed in [Table S2](#mmc3){ref-type="supplementary-material"}.

MNase-seq data were filtered for adaptor sequences and low-quality bases using Trim Galore with default parameters. Reads were aligned to the mouse reference genome GRCm38/mm10 using Bowtie ([@bib20]) with parameters "-y -m 1 --maxins 300 --allow-contain --nomaqround." The aligned reads were sorted and duplicates were removed using Picard tools (v1.114).

ChIP-seq binding sites for CTCF were obtained from the CODEX project ([@bib42]). Additional published ChIP-seq data referenced in this study are listed in [Table S3](#mmc4){ref-type="supplementary-material"}.

### Aggregate profiles of MNase-seq, Nascent RNA-seq and ChIP-seq {#sec4.4.5}

Aligned reads were converted to bigwig format at single-nucleotide resolution and normalized to uniform mean coverage using deeptools ([@bib36]) bamCoverage with parameters "--binSize 1--normalizeTo1x 2150570000" and using the "--blackListFileName" command on the mouseENCODE blacklisted regions ([@bib7]) for reference assembly GRCm38/mm10. Additionally, the option "--centerReads" was used on single end data and "--extendReads" was applied to all samples, with fragment length specified as 200 for transcription factor ChIP-seq and 250 for PolII ChIP-seq.

Aggregate profile data across different features were extracted from bigwig files using deepTools computeMatrix with parameters "--binSize 5 -b 1500 -a 1500 --missingDataAsZero" and using a bed file with the coordinates of the selected feature. The option "--referencePoint tss" was used for the tss coordinates and "--referencePoint center" for all other features. The resulting MNase-seq and ChIP-seq data were first normalized by the mean signal at each individual location. The aggregate signal for across all locations per replicate was further normalized by dividing it by the mean signal at flanking positions −1500 to −1450 and +1450 to +1500, to yield enrichment over baseline using a consistent baseline across all replicates. Nascent RNA-seq data were not treated with these normalization steps. The final aggregate profiles display the mean of the three biological replicates. A 95% confidence interval of the MNase-seq and ChIP-seq mean was calculated by bootstrapping, with 5000 iterations for each biological sample replicate and with the normalization procedure repeated independently. A 95% confidence interval of the nascent RNA-seq mean was calculated as ± 1.96 s.e.m. Empirical p values were computed based on the bootstrap replicates.

Transcription start site coordinates were extracted from Gencode vM9.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Data analysis and statistical tests for qPCR data were performed using GraphPad Prism, and p values calculated using a two-tailed t test. P values for high throughput sequencing data were calculated using bootstrapping.

Data and Software Availability {#sec4.6}
------------------------------

Sequencing data are available in the ArrayExpress repository under accessions E-MTAB-6804 (ChIP-seq), E-MTAB-6805 (nascent RNA-seq), E-MTAB-6806 (total RNA-seq) and E-MTAB-6807 (MNase-seq).
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